Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · GeneDx Holdings Corp. (WGS)

GeneDx Q3 revenue rises 5% to $123.1 million; full-year revenue guidance reiterated

Mixed Impact 4 of 5 guidance

GeneDx reported third quarter 2026 revenue of $123.1 million, up 5% year-over-year, and exome and genome volume growth of 25%. The company reiterated its full-year 2026 revenue guidance of $475 to $490 million, but the guidance table shows lower growth targets for exome and genome volume and revenue than the previous guidance. Adjusted net income fell from $16.1 million a year earlier, and the GAAP net loss widened to $12.3 million.

Key points

  • Q3 2026 revenue $123.1 million, up 5% year-over-year; exome and genome revenue $110.4 million, up 12%
  • Adjusted net income $8.6 million versus $16.1 million in Q3 2025; GAAP net loss $12.3 million versus $7.6 million a year earlier
  • Full-year 2026 exome and genome volume growth target listed as at least 28%, versus at least 30% previously; exome and genome revenue growth target at least 17%, versus at least 20% previously
  • Q4 2026 guidance: revenue $135 million, exome and genome revenue $121 million, 34,500 tests

The filing

CompanyGeneDx Holdings Corp. (WGS)
Form8-K, current report
Filed with the SECNov 9, 2026, 4:10 PM ET
Accession number0001628280-26-072172

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 7:16 PM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.